Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.850
EU - Europa 2.318
AS - Asia 632
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AF - Africa 1
Totale 10.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.845
IT - Italia 649
FI - Finlandia 556
CN - Cina 487
DE - Germania 237
UA - Ucraina 205
IE - Irlanda 156
GB - Regno Unito 134
SE - Svezia 112
RU - Federazione Russa 85
RO - Romania 54
BE - Belgio 46
FR - Francia 43
IN - India 40
TR - Turchia 29
KR - Corea 22
IR - Iran 15
CH - Svizzera 9
ES - Italia 8
HK - Hong Kong 7
NL - Olanda 7
UZ - Uzbekistan 7
PL - Polonia 6
BR - Brasile 5
EU - Europa 5
CA - Canada 4
CL - Cile 4
LB - Libano 4
IL - Israele 3
KZ - Kazakistan 3
TW - Taiwan 3
AR - Argentina 2
AU - Australia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
GR - Grecia 2
ID - Indonesia 2
JP - Giappone 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
EE - Estonia 1
LU - Lussemburgo 1
MA - Marocco 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
SG - Singapore 1
VN - Vietnam 1
Totale 10.825
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 778
Woodbridge 765
Wilmington 575
Chandler 572
Seattle 570
Houston 529
Cambridge 526
Ann Arbor 494
Palermo 168
Dublin 154
Medford 141
Des Moines 122
Altamura 118
Nanjing 109
Jacksonville 107
Princeton 90
Lawrence 80
San Diego 71
Beijing 54
Boardman 53
Dearborn 50
New York 50
Brussels 45
Tulsa 41
Ludwigshafen am Rhein 39
Changsha 36
London 33
Nanchang 33
Shenyang 33
Phoenix 32
Hebei 29
Jiaxing 28
Bremen 27
Izmir 25
Tianjin 25
Jinan 22
Kumar 21
Helsinki 20
Saint Petersburg 20
Seongnam 20
Zhengzhou 18
Ningbo 16
San Paolo di Civitate 15
Milan 14
Hangzhou 12
Venice 12
Chicago 11
Washington 11
Guangzhou 10
Los Angeles 10
Tehran 9
Norwalk 8
Pune 8
Rome 8
Verona 8
Kilburn 7
Hong Kong 6
Taiyuan 6
Auburn Hills 5
Frankfurt Am Main 5
Fuzhou 5
Hanover 5
Kunming 5
Orange 5
San Mateo 5
Cagliari 4
Frankfurt am Main 4
Indiana 4
Islington 4
Moscow 4
Mountain View 4
Redmond 4
Redwood City 4
Taizhou 4
Tappahannock 4
Chengdu 3
Detroit 3
Haikou 3
Hefei 3
Marano di Napoli 3
Montepulciano 3
Napoli 3
New Delhi 3
Nürnberg 3
San Francisco 3
Taipei 3
Vigliano Biellese 3
Walnut 3
Wandsworth 3
Zurich 3
Amsterdam 2
Aragona 2
Atlanta 2
Bene Beraq 2
Bologna 2
Brugherio 2
Buffalo 2
Chiclayo 2
Chiswick 2
Totale 8.471
Salva come PNG Salva come JPEG
Nome #
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 210
Dietary restriction: could it be considered as speed bump on tumor progression road? 205
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 191
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 187
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 177
EGFR genomic alterations in cancer: prognostic and predictive values 174
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 172
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 171
A headlight on liquid biopsies: a challenging tool for breast cancer management 168
HER2-positive male breast cancer: An update 166
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 165
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 164
Anti-endothelin drugs in solid tumors 161
Targeted Therapies in Hepatocellular Carcinoma 160
Nintedanib in NSCLC: Evidence to date and place in therapy 159
Monoclonal antibodies in gastrointestinal cancers 158
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 157
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 156
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 153
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 153
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 152
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 151
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 149
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 148
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 147
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 147
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 146
The role of targeted therapy for gastrointestinal tumors 146
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 145
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 144
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 143
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 142
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 141
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 141
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 140
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 138
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 136
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 136
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 135
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 135
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 134
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 133
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 132
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 131
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 130
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 130
Sex steroids, carcinogenesis, and cancer progression 130
Well-being among Italian medical oncologists: An exploratory study 128
Cancer and the microbiome: Potential applications as new tumor biomarker 128
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 127
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 127
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 126
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 126
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 124
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 123
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 122
Multisciplinary management of patients with liver metastasis from colorectal cancer 121
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 119
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 117
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 115
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 115
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 113
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 111
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 109
Ramucirumab and its use in gastric cancer treatment 102
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 102
Bortezomib: a new pro-apoptotic agent in cancer treatment. 101
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 101
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 99
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 95
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 95
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 91
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 90
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 89
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 83
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 82
Apoptosis in Thyroid Autoimunity. 81
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 80
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 74
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 73
VIPoma and PPoma 73
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 70
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 68
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 67
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 62
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 61
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 61
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 60
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 51
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 40
Totale 11.291
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.354
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019642 0 0 0 0 0 0 0 0 0 0 326 316
2019/20203.517 322 153 252 635 401 392 323 266 291 187 210 85
2020/20211.493 117 82 88 130 85 32 124 118 162 224 159 172
2021/20221.317 58 284 72 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024566 29 87 51 51 47 132 64 86 7 10 2 0
Totale 11.291